Ascendis Pharma Q2 Net Profit €207M, Revenue €339M; YUVIWEL Approved
Ascendis Pharma reported a strong financial performance for Q2 and H1 2026, swinging from a net loss to a substantial net profit. Q2 2026 net profit reached €206.97 million on revenue of €339.28 million, driven by the U.S. FDA approval of YUVIWEL® (navepegritide) and the subsequent sale of a Rare Pediatric Disease Priority Review Voucher for $187.5 million. The company also completed the redemption of $575 million in convertible notes and executed a $120 million share repurchase program during the period.
Key Highlights
- Q2 2026 Net Profit: €206.97 million, a significant turnaround from €(38.85) million loss in Q2 2025.
- Q2 2026 Revenue: €339.28 million, up 114.7% from €158.04 million in Q2 2025.
- H1 2026 Net Profit: €836.31 million, compared to a €(133.48) million loss in H1 2025.
- H1 2026 Revenue: €585.89 million, an increase of 126.2% from €258.99 million in H1 2025.
- YUVIWEL® (navepegritide) received U.S. FDA approval in February 2026.
- Sold Rare Pediatric Disease PRV for $187.5 million, generating €158.1 million in other operating income.
- Redeemed $575 million outstanding 2.25% convertible notes in May 2026.
- Repurchased $120 million of ordinary shares under a share repurchase program.
Price Impact
More from ASND
Ascendis Pharma to Present Long-Term Data on Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
Ascendis Pharma Q2 2026 Product Revenue +105% to €315M; Net Profit €207M
Ascendis Pharma Q2 Product Revenue €315M, +105% Y/Y